This application relates to combination compositions for use in treatment of depression, comprising an effective amount of an N-methyl-D-aspartate receptor (NMDAR) antagonist combined with an anti-depressant agent or an atypical antipsychotic approved for treatment of depression. In a preferred embodiment, D-cycloserine is administered at a dose of about 10 mg/kg/d and is formulated to produce sustained blood levels in excess of about 25 microgram/mL.

This application relates to combination compositions for use in treatment of depression, comprising an effective amount of an N-methyl-D-aspartate receptor (NMDAR) antagonist combined with an anti-depressant agent or an atypical antipsychotic approved for treatment of depression. In a preferred embodiment, D-cycloserine is administered at a dose of about 10 mg/kg/d and is formulated to produce sustained blood levels in excess of about 25 microgram/mL.

The present disclosure relates to methods and compositions which prevent and protect against all three types of stress-induced maladaptive behaviors- fear, depressive-like, and anxiety-like behavior, which in turn can prevent a wide variety of stress-induced fear, anxiety, and depressive disorders. In some aspects, the compositions and methods use a serotonin 4 receptor (5-hydroxytryptamine (serotonin) receptor 4, or 5-HT.sub.4R) agonist in combination with: ketamine, a ketamine analog, or a pharmaceutically acceptable salt, derivative, or metabolite thereof; an antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor (NMDAR); or an agonist of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (AMPAR). In certain aspects, the present composition or compositions can be administered prior to a stressor. In certain aspects, the present composition or compositions can be administered after a stressor.

The present disclosure relates to methods and compositions which prevent and protect against all three types of stress-induced maladaptive behaviors- fear, depressive-like, and anxiety-like behavior, which in turn can prevent a wide variety of stress-induced fear, anxiety, and depressive disorders. In some aspects, the compositions and methods use a serotonin 4 receptor (5-hydroxytryptamine (serotonin) receptor 4, or 5-HT.sub.4R) agonist in combination with: ketamine, a ketamine analog, or a pharmaceutically acceptable salt, derivative, or metabolite thereof; an antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor (NMDAR); or an agonist of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (AMPAR). In certain aspects, the present composition or compositions can be administered prior to a stressor. In certain aspects, the present composition or compositions can be administered after a stressor.

The present disclosure relates to methods and compositions which prevent and protect against all three types of stress-induced maladaptive behaviors- fear, depressive-like, and anxiety-like behavior, which in turn can prevent a wide variety of stress-induced fear, anxiety, and depressive disorders. In some aspects, the compositions and methods use a serotonin 4 receptor (5-hydroxytryptamine (serotonin) receptor 4, or 5-HT.sub.4R) agonist in combination with: ketamine, a ketamine analog, or a pharmaceutically acceptable salt, derivative, or metabolite thereof; an antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor (NMDAR); or an agonist of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (AMPAR). In certain aspects, the present composition or compositions can be administered prior to a stressor. In certain aspects, the present composition or compositions can be administered after a stressor.

The present invention provides a method for safe and efficacious administration of esketamine.

The present invention provides a method for safe and efficacious administration of esketamine.

The present disclosure discloses a compound shown in formula (II) and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound as an active ingredient, and use thereof in the preparation of medicaments for protein degradation.

##STR00001##

Disclosed are anti-avian pathogenic E. coli (APEC) agents as well as methods of using thereof.

Disclosed are anti-avian pathogenic E. coli (APEC) agents as well as methods of using thereof.